POLITICS

Washington launches TrumpRx website to lower drug costs

PUBLISHED Feb 5, 2026, 12:51 PM ET

Read, Watch or Listen

Media Bias Meter

Sources: 11

Center 91%

Right 9%

Sources: 11

Washington — President Donald Trump unveiled TrumpRx.gov on Thursday, a website designed to connect consumers with discounted prescription medicines. The White House announced a 7 p.m. ET launch and said the site will link users to manufacturers’ direct-purchase platforms rather than dispense drugs. Trump announced the initiative with CMS Administrator Dr. Mehmet Oz and National Design Studio Director Joe Gebbia. The administration said over a dozen drugmakers signed most-favored-nation agreements to offer lower cash prices, with GoodRx named a key integration partner. Officials said some GLP-1 prices could fall to $149–$350 per month. Based on 6 articles reviewed and supporting research.

By Najma A. | JQJO News

Timeline of Events

September 2025: Administration first announced plans for a TrumpRx initiative to lower drug prices.
December 2025: Trump publicly described the forthcoming site as delivering substantial consumer discounts.
5 February 2026 (scheduled): White House announced the 7:00 PM ET unveiling of TrumpRx.gov.
5 February 2026, 7:00 PM ET: President Trump unveiled TrumpRx at the White House with Dr. Mehmet Oz and Joe Gebbia.
Post-launch: TrumpRx went live as a portal listing manufacturer cash prices; GoodRx integration was confirmed and MFN deals with multiple drugmakers were cited, including GLP-1 price targets.

Media Bias

Articles Published:: 11
Right Leaning:: 1
Left Leaning:: 0
Neutral:: 10
Distribution:: Left 0%, Center 91%, Right 9%

Who Benefited

Consumers paying cash for prescription drugs may benefit from lower listed cash prices via TrumpRx, participating drugmakers may gain broader U.S. market access under MFN arrangements, and partners like GoodRx could see increased transaction volume.

Who Impacted

Non-participating pharmacies and intermediaries could lose cash sales; patients without direct manufacturer channels or who rely on pharmacy dispensing may still face access or practical barriers despite listed discounts.